ReviewWiener klinische Wochenschrift2022
Update of the mechanism and characteristics of tuberculosis in chronic kidney disease : Review article.
Review in Wiener klinische Wochenschrift, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Cerebral Abscess Masquerading as Tuberculoma in a Post-Renal Transplant Chronic Kidney Disease Patient: A Diagnostic and Therapeutic Challenge.Clinical case reports · 2026Article
- Non-communicable comorbidities in pulmonary tuberculosis and healthcare utilization: a cross-sectional study of 2021 Indonesian national health insurance data.Archives of public health = Archives belges de sante publique · 2024Article
- Diagnosis of Latent Tuberculosis Infection in Hemodialysis Patients: TST versus T-SPOT.TB.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The risk of tuberculosis (TB) is significantly increased in patients with chronic kidney disease (CKD), which is closely related to hyperparathyroidism, malnutrition and oxidative stress as well as immune deficiency in patients with end-stage renal disease (ESRD). Vitamin D deficiency and gender bias are independent risk factors. In the TB screening and diagnosis test of CKD, interferon-gamma release assays (IGRA), including T‑SPOT.TB test (T-SPOT) and QuantiFERON-TB Gold In-Tube (QFT-GIT) have been available. Many studies have found that they are more sensitive and specific than tuberculin skin test (TST). At present, IGRA has been used to study various types of immunocompromised patients. For CKD patients with TB, the choice and dosage of anti-TB drugs need to be reconsidered. Weekly treatment with rifapentin (RFT) and isoniazid (INH) for 3 months is an effective treatment for latent tuberculosis infection (LTBI) in hemodialysis (HD) patients. Therefore, in this review we discuss CKD and TB, its pathogenesis, clinical features, diagnosis and treatment advancements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.